Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Seung Ah Jun

Ji Young Song

Young Gil Ahn

In Hwan Bae

Ho Seok Kim

Eun Young Byun

Kwee Hyun Suh

Jung Beom Son

Eun Joo Kwak

Young Hee Jung

Sang Mi Han

Maeng Sup Kim

Seung Hyun Jung

Mi Yon Shim

Hae Kyoung Ju

Kyung Ik Lee

The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-&#x3b2;, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Pyrazole derivative as ALK5 inhibitor and uses thereof

Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Thieno[3,2-D]pyrimidine derivatives having inhibitory activity for protein kinases

Provided is a pharmaceutical composition comprising, as an active ingredient, a quinoline or quinazoline derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof, which is effective in the prevention and treatment of a cancer, inflammation, autoimmune diseases or neurodegenerative disorders which are induced by the overexpression of inhibitor of apoptosis proteins (IAPs).

Quinoline or quinazoline derivatives with apoptosis inducing activity on cells

Growing community of inventors

Busan, South Korea

Seung Ah Jun